procainamide has been researched along with Disease Models, Animal in 49 studies
Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.
procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In adrenergically stimulated anesthetized rabbits, azimilide, clofilium, dofetilide, sematilide, and d,l-sotalol caused premature ventricular contractions and nonsustained and sustained ventricular tachyarrhythmias (NSVT and SVT) at pharmacologically equivalent intravenous doses that increased QTc intervals 20% (ED20)." | 7.70 | Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. ( Al-Khalidi, H; Brooks, RR; Drexler, AP; Kostreva, DR; Maynard, AE, 2000) |
| "The effects of procainamide and propafenone on the composition of the excitable gap (EG) were studied in a canine model of atrial flutter (AFI) around the tricuspid valve." | 7.69 | Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia. ( Derakhchan, K; Kus, T; Lambert, C; Pagé, P, 1994) |
| "The effects of increasing concentrations of procainamide on the composition of the excitable gap were determined in a canine model of atrial flutter." | 7.69 | Effects of procainamide on the excitable gap composition in a canine model of atrial flutter. ( Jalil, E; Kus, T; Laflamme, M, 1997) |
| "To evaluate the mechanisms of action of procainamide on the components of the reentrant pathway, drug-induced changes in activation patterns, effective refractory periods (ERPs), and stimulation thresholds were analyzed in nine dogs with sterile pericarditis and sustained atrial flutter." | 7.68 | Circus movement atrial flutter in the canine sterile pericarditis model. Differential effects of procainamide on the components of the reentrant pathway. ( el-Sherif, N; Gough, WB; Schoels, W; Yang, H, 1991) |
| "Heavy male Sprague-Dawley rats die of ventricular fibrillation within 2 to 3 h after isoproterenol administration." | 7.67 | Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death. ( Balazs, T; Ehrreich, SJ; el-Hage, AN; Johnson, GL, 1986) |
| "The efficacy of intravenous cibenzoline (3 mg/kg), propafenone (4 mg/kg), and procainamide (20 mg/kg) against inducible sustained and nonsustained ventricular tachycardias (VT) was evaluated in 12 conscious dogs with chronic isolated right ventricular (RV) infarction." | 7.67 | The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide. ( Ino, T; Karagueuzian, HS; Mandel, WJ; Meesmann, M; Ohta, M; Peter, T; Sugi, K, 1986) |
| "Lidocaine pretreatment (10 mg/kg i." | 5.26 | Acute coronary artery occlusion-reperfusion-induced arrhythmias in rats, dogs and pigs: antiarrhythmic evaluation of quinidine, procainamide and lidocaine. ( Bergey, JL; McCallum, JD; Nocella, K, 1982) |
| "Antiarrhythmic properties of taurhythman were demonstrated on experimental models of ventricular (early occlusion and calcium chloride-induced) and atrioventricular (aconitine-induced) arrhythmias." | 3.73 | Antiarrhythmic activity of taurhythman. ( Evdokimova, NR; Gavrovskaya, LK; Krylova, IB; Sapronov, NS, 2005) |
| " This exhibited features similar to human lupus and was induced by injecting mice either with the H308 monoclonal antibody specific to NPA, with sera from mice which already had developed the autoimmune disease, or with liposomes treated with the NPA inductors chlorpromazine or procainamide; or with these NPA inductors alone." | 3.72 | Antibodies to non-bilayer phospholipid arrangements induce a murine autoimmune disease resembling human lupus. ( Baeza, I; Campos, B; Farfán, N; Flores-Romo, L; Hernández-Pando, R; Ibáñez, M; Lara, M; Leyva, E; Orozco, H; Wong, C, 2004) |
| "5 mg/kg cumulative pericardial procainamide doses prolonged atrial refractoriness and raised atrial fibrillation threshold similar to the 26 mg/kg cumulative intravenous dose, but the duration of effect was similar between delivery methods." | 3.71 | Intrapericardial therapeutics: a pharmacodynamic and pharmacokinetic comparison between pericardial and intravenous procainamide delivery. ( Euler, DE; Hadsall, KZ; Mehra, R; Ujhelyi, MR, 2002) |
| " In adrenergically stimulated anesthetized rabbits, azimilide, clofilium, dofetilide, sematilide, and d,l-sotalol caused premature ventricular contractions and nonsustained and sustained ventricular tachyarrhythmias (NSVT and SVT) at pharmacologically equivalent intravenous doses that increased QTc intervals 20% (ED20)." | 3.70 | Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit. ( Al-Khalidi, H; Brooks, RR; Drexler, AP; Kostreva, DR; Maynard, AE, 2000) |
| "The effects of procainamide and propafenone on the composition of the excitable gap (EG) were studied in a canine model of atrial flutter (AFI) around the tricuspid valve." | 3.69 | Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia. ( Derakhchan, K; Kus, T; Lambert, C; Pagé, P, 1994) |
| "To evaluate the effects of programmed ventricular stimulation on resultant plasma concentrations of intravenously administered procainamide, drug dosing was performed with and without ventricular stimulation on two separate days (48 hours apart) in 12 dogs (13 dosing trials) at > or = 14 days after myocardial infarction (mean: 62 days)." | 3.69 | The effects of programmed ventricular stimulation on plasma procainamide levels: an experimental model. ( Brautigam, RT; Kutalek, SP; Porter, S, 1994) |
| "The effects of increasing concentrations of procainamide on the composition of the excitable gap were determined in a canine model of atrial flutter." | 3.69 | Effects of procainamide on the excitable gap composition in a canine model of atrial flutter. ( Jalil, E; Kus, T; Laflamme, M, 1997) |
| "To evaluate the mechanisms of action of procainamide on the components of the reentrant pathway, drug-induced changes in activation patterns, effective refractory periods (ERPs), and stimulation thresholds were analyzed in nine dogs with sterile pericarditis and sustained atrial flutter." | 3.68 | Circus movement atrial flutter in the canine sterile pericarditis model. Differential effects of procainamide on the components of the reentrant pathway. ( el-Sherif, N; Gough, WB; Schoels, W; Yang, H, 1991) |
| " In these models it is more potent than lidocaine, procainamide and quinidine, as well as a number of investigational agents, and is active against both ventricular and supraventricular arrhythmias from a number of causes." | 3.67 | Antiarrhythmic and electrophysiologic actions of flecainide in animal models. ( Banitt, EH; Kvam, DC; Schmid, JR, 1984) |
| "Heavy male Sprague-Dawley rats die of ventricular fibrillation within 2 to 3 h after isoproterenol administration." | 3.67 | Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death. ( Balazs, T; Ehrreich, SJ; el-Hage, AN; Johnson, GL, 1986) |
| "The efficacy of intravenous cibenzoline (3 mg/kg), propafenone (4 mg/kg), and procainamide (20 mg/kg) against inducible sustained and nonsustained ventricular tachycardias (VT) was evaluated in 12 conscious dogs with chronic isolated right ventricular (RV) infarction." | 3.67 | The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide. ( Ino, T; Karagueuzian, HS; Mandel, WJ; Meesmann, M; Ohta, M; Peter, T; Sugi, K, 1986) |
| "CHARGE syndrome is an autosomal dominant congenital disorder caused primarily by mutations in the CHD7 gene." | 1.56 | Chemical screens in a zebrafish model of CHARGE syndrome identifies small molecules that ameliorate disease-like phenotypes in embryo. ( Asad, Z; Sachidanandan, C, 2020) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in the cardiac ryanodine receptor (RyR2) or calsequestrin (Casq2) and can be difficult to treat." | 1.37 | Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. ( Faggioni, M; Hasdemir, C; Hwang, HS; Knollmann, BC; Laver, D; Mehra, D; Turhan, K; Yin, H, 2011) |
| "By nine weeks, one TG(N488I) mouse with WPW syndrome lost this phenotype, whereas TG(WT) pups never developed pre-excitation." | 1.32 | Electrophysiologic characterization and postnatal development of ventricular pre-excitation in a mouse model of cardiac hypertrophy and Wolff-Parkinson-White syndrome. ( Arad, M; Berul, CI; Branco, D; Maguire, CT; Moskowitz, IP; Patel, VV; Seidman, CE; Seidman, JG, 2003) |
| " The toxicity of these compounds against hepatoma cells (MH3924A) and, to a lesser extent, against mouse fibroblast (NIH 3T3) and cervix carcinoma (HeLa) cells was also enhanced, but they were not as toxic as dacarbazine (HeLa)." | 1.32 | Alkylating benzamides with melanoma cytotoxicity. ( Bauder-Wüst, U; Eisenhut, M; Haberkorn, U; Mier, W; Mohammed, A; Schönsiegel, F; Wolf, M, 2004) |
| "Procainamide was administrated intravenously at a dose of 15 mg/kg after the control study and the whole study protocol was repeated." | 1.31 | Effect of procainamide on the postrepolarization refractoriness in cardiac muscle: evaluation using the block coupling interval in the artificial isthmus model in the canine right atrium. ( Inuo, K; Izumi, T; Kitano, Y; Moriguchi, M; Niwano, S; Saito, J; Yoshizawa, N, 2001) |
| "Lidocaine pretreatment (10 mg/kg i." | 1.26 | Acute coronary artery occlusion-reperfusion-induced arrhythmias in rats, dogs and pigs: antiarrhythmic evaluation of quinidine, procainamide and lidocaine. ( Bergey, JL; McCallum, JD; Nocella, K, 1982) |
| "The average plasma level required for arrhythmia control in these patients was equivalent to 5." | 1.25 | Antiarrhythmic potency of N-acetylprocainamide. ( Atkinson, AJ; Elson, J; Lee, WK; Strong, JM, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (44.90) | 18.7374 |
| 1990's | 11 (22.45) | 18.2507 |
| 2000's | 11 (22.45) | 29.6817 |
| 2010's | 2 (4.08) | 24.3611 |
| 2020's | 3 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Bernard, H | 1 |
| Teijeiro, A | 1 |
| Chaves-Pérez, A | 1 |
| Perna, C | 1 |
| Satish, B | 1 |
| Novials, A | 1 |
| Wang, JP | 1 |
| Djouder, N | 1 |
| Asad, Z | 1 |
| Sachidanandan, C | 1 |
| Hwang, HS | 1 |
| Hasdemir, C | 1 |
| Laver, D | 1 |
| Mehra, D | 1 |
| Turhan, K | 1 |
| Faggioni, M | 1 |
| Yin, H | 1 |
| Knollmann, BC | 1 |
| Natori, S | 1 |
| Hasebe, N | 1 |
| Jin, YT | 1 |
| Matsusaka, T | 1 |
| Ido, A | 1 |
| Matsuhashi, H | 1 |
| Ihara, T | 1 |
| Kikuchi, K | 1 |
| Deng, C | 1 |
| Lu, Q | 1 |
| Zhang, Z | 1 |
| Rao, T | 1 |
| Attwood, J | 1 |
| Yung, R | 2 |
| Richardson, B | 2 |
| Patel, VV | 1 |
| Arad, M | 1 |
| Moskowitz, IP | 1 |
| Maguire, CT | 1 |
| Branco, D | 1 |
| Seidman, JG | 1 |
| Seidman, CE | 1 |
| Berul, CI | 1 |
| Rosário, LB | 1 |
| Rocha, I | 1 |
| Silva-Carvalho, L | 1 |
| Baeza, I | 1 |
| Leyva, E | 1 |
| Campos, B | 1 |
| Lara, M | 1 |
| Ibáñez, M | 1 |
| Farfán, N | 1 |
| Orozco, H | 1 |
| Flores-Romo, L | 1 |
| Hernández-Pando, R | 1 |
| Wong, C | 1 |
| Wolf, M | 1 |
| Bauder-Wüst, U | 1 |
| Mohammed, A | 1 |
| Schönsiegel, F | 1 |
| Mier, W | 1 |
| Haberkorn, U | 1 |
| Eisenhut, M | 1 |
| Sapronov, NS | 1 |
| Gavrovskaya, LK | 1 |
| Krylova, IB | 1 |
| Evdokimova, NR | 1 |
| Kluger, J | 1 |
| Horner, H | 1 |
| Reidenberg, MM | 1 |
| Kvam, DC | 1 |
| Banitt, EH | 1 |
| Schmid, JR | 1 |
| Weber, WW | 1 |
| Tannen, RH | 1 |
| Hall, GM | 1 |
| Lucke, JN | 1 |
| Lister, D | 1 |
| Bergey, JL | 1 |
| Nocella, K | 1 |
| McCallum, JD | 1 |
| Ettinger, PO | 1 |
| Moore, RJ | 1 |
| Calabro, J | 1 |
| Oldewurtel, HA | 1 |
| Regan, TJ | 2 |
| Derakhchan, K | 1 |
| Pagé, P | 1 |
| Lambert, C | 1 |
| Kus, T | 2 |
| Brautigam, RT | 1 |
| Porter, S | 1 |
| Kutalek, SP | 1 |
| Xue, YX | 1 |
| Eto, K | 1 |
| Akie, Y | 1 |
| Hashimoto, K | 1 |
| Jalil, E | 1 |
| Laflamme, M | 1 |
| Kretz-Rommel, A | 2 |
| Duncan, SR | 1 |
| Rubin, RL | 2 |
| Williams, R | 1 |
| Johnson, K | 1 |
| Phillips, C | 1 |
| Stoolman, L | 1 |
| Chang, S | 1 |
| Brooks, RR | 1 |
| Drexler, AP | 1 |
| Maynard, AE | 1 |
| Al-Khalidi, H | 1 |
| Kostreva, DR | 1 |
| Yoshizawa, N | 1 |
| Niwano, S | 1 |
| Moriguchi, M | 1 |
| Kitano, Y | 1 |
| Inuo, K | 1 |
| Saito, J | 1 |
| Izumi, T | 1 |
| Kudenchuk, PJ | 1 |
| Ujhelyi, MR | 1 |
| Hadsall, KZ | 1 |
| Euler, DE | 1 |
| Mehra, R | 1 |
| Nelson, TE | 1 |
| Flewellen, EH | 1 |
| Fox, JL | 1 |
| Nathan, MP | 1 |
| Haider, B | 1 |
| Ahmed, SS | 1 |
| Elson, J | 1 |
| Strong, JM | 1 |
| Lee, WK | 1 |
| Atkinson, AJ | 1 |
| Yeh, TM | 1 |
| Tami, JA | 1 |
| Krolick, KA | 1 |
| Schoels, W | 1 |
| Yang, H | 1 |
| Gough, WB | 1 |
| el-Sherif, N | 1 |
| Abu-Shakra, M | 1 |
| Shoenfeld, Y | 1 |
| Kirby, DA | 1 |
| Hottinger, S | 1 |
| Ravid, S | 1 |
| Lown, B | 1 |
| Johnson, GL | 1 |
| Ehrreich, SJ | 1 |
| el-Hage, AN | 1 |
| Balazs, T | 1 |
| Karagueuzian, HS | 1 |
| Sugi, K | 1 |
| Ohta, M | 1 |
| Meesmann, M | 1 |
| Ino, T | 1 |
| Peter, T | 1 |
| Mandel, WJ | 1 |
| Kaverina, NV | 1 |
| Senova, ZP | 1 |
| Vikxliàev, IuI | 1 |
| Ul'iànova, OV | 1 |
| Dorfmann, H | 1 |
| Kahn, MF | 1 |
| de Sèze, S | 1 |
| Faust, G | 1 |
| Fiedler, W | 1 |
| Lambert, PH | 1 |
| Creighton, D | 1 |
| Goodman, R | 1 |
| Bankhurst, A | 1 |
| Mischer, PA | 1 |
| Sinha, JN | 1 |
| Shamsi, MA | 1 |
| Kohli, RP | 1 |
| Bhargava, KP | 1 |
| Lee, MM | 1 |
| Vrbovský, L | 2 |
| Baum, T | 1 |
| Eckfeld, DK | 1 |
| Shropshire, AT | 1 |
| Rowles, G | 1 |
| Varner, LL | 1 |
| Blazek, Z | 1 |
| Vrána, M | 1 |
| Málek, P | 1 |
| Kolc, J | 1 |
5 reviews available for procainamide and Disease Models, Animal
| Article | Year |
|---|---|
Malignant hyperthermia--pearls out of swine?
Topics: Animals; Body Temperature; Dantrolene; Disease Models, Animal; Halothane; Magnesium Sulfate; Maligna | 1980 |
Advanced cardiac life support antiarrhythmic drugs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Bretylium Compounds; Cardiopulmonary Resuscitation; Cli | 2002 |
Human anti-DNA idiotype (16/6 idiotype): pathogenic role in autoimmunity.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Antinuclear; Antibodies, Monoclonal; Autoantibodies | 1990 |
[Iatrogenic lupus: present status of the problem. II. Physiopathology of induced lupus].
Topics: Animals; Antibodies, Antinuclear; Disease Models, Animal; DNA, Viral; Drug-Related Side Effects and | 1972 |
[Compounds with antiarrhythmic effects].
Topics: Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Animals, Laboratory; Anti-Arrhythmia Agent | 1973 |
44 other studies available for procainamide and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Coxsackievirus B Type 4 Infection in β Cells Downregulates the Chaperone Prefoldin URI to Induce a MODY4-like Diabetes via
Topics: Animals; Capsid Proteins; Coxsackievirus Infections; Diabetes Mellitus, Type 2; Disease Models, Anim | 2020 |
Chemical screens in a zebrafish model of CHARGE syndrome identifies small molecules that ameliorate disease-like phenotypes in embryo.
Topics: Animals; Animals, Genetically Modified; Cartilage; CHARGE Syndrome; Dipeptides; Disease Models, Anim | 2020 |
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calsequestrin; Defi | 2011 |
Inhaled nitric oxide modifies left ventricular diastolic stress in the presence of vasoactive agents in heart failure.
Topics: Acetylcholine; Administration, Inhalation; Angiotensin II; Animals; Diastole; Disease Models, Animal | 2003 |
Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling.
Topics: Animals; Autoimmunity; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine- | 2003 |
Electrophysiologic characterization and postnatal development of ventricular pre-excitation in a mouse model of cardiac hypertrophy and Wolff-Parkinson-White syndrome.
Topics: Adenosine; Age Factors; AMP-Activated Protein Kinases; Animals; Anti-Arrhythmia Agents; Biopsy; Card | 2003 |
Effect of losartan microinjections into the NTS on the cardiovascular components of chemically evoked reflexes in a rabbit model of acute heart ischemia.
Topics: Acute Disease; Animals; Capsaicin; Chemoreceptor Cells; Disease Models, Animal; Female; Losartan; Ma | 2003 |
Antibodies to non-bilayer phospholipid arrangements induce a murine autoimmune disease resembling human lupus.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Autoantibodies; Autoimmune Diseases; Chlorpro | 2004 |
Alkylating benzamides with melanoma cytotoxicity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Cell Line, Tumor; Cel | 2004 |
Antiarrhythmic activity of taurhythman.
Topics: Aconitine; Alkanesulfonic Acids; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiotonic | 2005 |
Effects of procainamide and N-acetylprocainamide on myocardial contractility in ischemic isolated rabbit hearts.
Topics: Acecainide; Animals; Coronary Disease; Disease Models, Animal; Epinephrine; Male; Myocardial Contrac | 1981 |
Antiarrhythmic and electrophysiologic actions of flecainide in animal models.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Do | 1984 |
Pharmacokinetic studies on the drug-related lupus syndrome. Differences in antinuclear antibody development and drug-induced DNA damage in rapid and slow acetylator animal models.
Topics: Acetylation; Animals; Antibodies, Antinuclear; Antibody Formation; Disease Models, Animal; DNA Repai | 1981 |
Acute coronary artery occlusion-reperfusion-induced arrhythmias in rats, dogs and pigs: antiarrhythmic evaluation of quinidine, procainamide and lidocaine.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Coronary Disease; Disease Models, Animal; Dogs; Femal | 1982 |
Ventricular tachyarrhythmias in regional myocardial hyperkalemia: efficacy of three antiarrhythmic agents.
Topics: Animals; Coronary Disease; Disease Models, Animal; Dogs; Electrocardiography; Heart Conduction Syste | 1980 |
Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia.
Topics: Action Potentials; Anesthesia; Animals; Atrial Flutter; Atrial Function; Chloralose; Diastole; Disea | 1994 |
The effects of programmed ventricular stimulation on plasma procainamide levels: an experimental model.
Topics: Animals; Blood Pressure; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiography; My | 1994 |
Antiarrhythmic and proarrhythmic effects of sematilide in canine ventricular arrhythmia models.
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Ele | 1996 |
Effects of procainamide on the excitable gap composition in a canine model of atrial flutter.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Flutter; Diastole; Disease Models, Animal | 1997 |
Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus.
Topics: Adoptive Transfer; Animals; Antibodies, Antinuclear; Autoimmunity; Disease Models, Animal; Female; H | 1997 |
Mechanisms of drug-induced lupus. III. Sex-specific differences in T cell homing may explain increased disease severity in female mice.
Topics: Adoptive Transfer; Animals; Antibodies, Antinuclear; Autoantibodies; Autoimmune Diseases; Chemical a | 1997 |
Persistence of autoreactive T cell drive is required to elicit anti-chromatin antibodies in a murine model of drug-induced lupus.
Topics: Adoptive Transfer; Age Factors; Animals; Antibodies, Antinuclear; Autoantigens; Chromatin; Disease M | 1999 |
Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit.
Topics: Adrenergic alpha-Agonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, An | 2000 |
Effect of procainamide on the postrepolarization refractoriness in cardiac muscle: evaluation using the block coupling interval in the artificial isthmus model in the canine right atrium.
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dogs; Electrophysiology; Heart Block; Heart | 2001 |
Intrapericardial therapeutics: a pharmacodynamic and pharmacokinetic comparison between pericardial and intravenous procainamide delivery.
Topics: Action Potentials; Animals; Atrial Fibrillation; Cardiovascular Agents; Disease Models, Animal; Dose | 2002 |
Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia.
Topics: Animals; Dantrolene; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Halothane; Hy | 1979 |
Effects of procainamide and chloramphenicol on acute vasospasm.
Topics: Acute Disease; Administration, Topical; Animals; Basilar Artery; Chloramphenicol; Disease Models, An | 1977 |
Spontaneous heart rate, ventricular tachycardia, and the response to procainamide during acute ischemia.
Topics: Animals; Arrhythmias, Cardiac; Coronary Disease; Disease Models, Animal; Dogs; Heart; Heart Rate; Ma | 1977 |
Antiarrhythmic potency of N-acetylprocainamide.
Topics: Animals; Arrhythmias, Cardiac; Chloroform; Chromatography, Gas; Disease Models, Animal; Dose-Respons | 1975 |
Exacerbated muscle dysfunction by procainamide in rats with experimental myasthenia gravis.
Topics: Animals; Antibodies; Autoimmune Diseases; Disease Models, Animal; Dose-Response Relationship, Drug; | 1992 |
Circus movement atrial flutter in the canine sterile pericarditis model. Differential effects of procainamide on the components of the reentrant pathway.
Topics: Animals; Atrial Flutter; Disease Models, Animal; Dogs; Electrocardiography; Heart; Heart Conduction | 1991 |
Inducible monomorphic sustained ventricular tachycardia in the conscious pig.
Topics: Animals; Coronary Vessels; Disease Models, Animal; Heart Ventricles; Hemodynamics; Lidocaine; Ligati | 1990 |
Effects of antiarrhythmic agents on isoproterenol-induced ventricular fibrillation in heavy rats: a possible model of sudden cardiac death.
Topics: Animals; Anti-Arrhythmia Agents; Body Weight; Bretylium Tosylate; Death, Sudden; Disease Models, Ani | 1986 |
The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Drug Eval | 1986 |
[Antiarrhythimic properties of ethmozine].
Topics: Aconitum; Animals; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillat | 1970 |
[Experimental approach to the pathogenesis of systemic lupus erythematosus].
Topics: Animals; Antigen-Antibody Complex; Autoantibodies; Cyclophosphamide; Disease Models, Animal; DNA; Fe | 1972 |
Centrogenic cardiac arrhythmia induced by aconitine: a new "model" for screening of anti-arrhythmic drugs.
Topics: Adrenergic beta-Antagonists; Alkaloids; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood | 1971 |
Morphologic effects of procaine amide on mouse kidney as observed by scanning and by transmission electron microscopy.
Topics: Animals; Basement Membrane; Disease Models, Animal; Female; Kidney Glomerulus; Lupus Erythematosus, | 1974 |
[Comparison of the effect of various antiarrhythmic drugs on the model of experimental epinephrine arrhythmia].
Topics: Amides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cats; Disease Models, Animal; Dogs; E | 1973 |
Observations on models used for the evaluation of antiarrhythmic drugs.
Topics: Alkaloids; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutte | 1971 |
[Relative effectiveness of various antiarrhythmia drugs in experimental aconitine arrhythmia].
Topics: Aconitum; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Disease Models, Anim | 1971 |
Contribution to measurements of myocardial excitability.
Topics: Animals; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiography; Heart; Hemodynamic | 1971 |